Trial reportFrontiers in nutrition2025
Effect of preoperative oral isomaltulose on insulin resistance and glycemic variability in patients with type 2 diabetes mellitus: a randomized controlled trial.
Trial report in Frontiers in nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/objectives: Preoperative oral carbohydrate alleviates postoperative insulin resistance and enhances recovery. Its utility in type 2 diabetes mellitus (T2DM) is debated due to hyperglycemia risks. Isomaltulose, a low-glycemic-index carbohydrate, has been shown to effectively attenuate postprandial glucose fluctuations and reduce metabolic stress on pancreatic β-cells in T2DM patients. This study investigated the effects of preoperative oral isomaltulose in patients with T2DM undergoing elective laparoscopic non-gastrointestinal surgery. Methods: 60 T2DM patients were randomized to receive either 300 mL of a solution containing 50 g isomaltulose (isomaltulose group) or plain water (Control group) 2-3 h preoperatively. The primary outcome was insulin resistance, assessed by the homeostasis model assessment (HOMA-IR) at 24 h post surgery. Secondary outcomes included perioperative glycemic variability, serum insulin levels, Perlas grade (assessed by pre-anesthesia gastric ultrasound), incidence of regurgitation and aspiration, perioperative subjective comfort scores, postoperative nausea and vomiting incidence (PONV), time of first flatus after surgery, surgical wound complications, length of postoperative hospital stay. Results: Baseline characteristics were comparable. At 24 h postoperatively, the Isomaltulose group exhibited significantly lower HOMA-IR [6.89 ± 3.38 vs. 11.60 ± 4.34; mean difference = 4.71, 95% CI (2.70, 6.72), Conclusion: In well-controlled T2DM patients, preoperative oral isomaltulose was associated with lower postoperative insulin resistance and reduced glycemic variability, without delaying gastric emptying. These metabolic benefits were accompanied by a transient elevation in pre-induction blood glucose, which should be weighed in clinical decision making. Clinical trial registration: https://www.chictr.org.cn/index.html, identifier ChiCTR2500098088.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.